サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1494499

北米の神経刺激装置：2030年市場予測-地域別分析-製品別、用途別、エンドユーザー別

North America Neurostimulation Devices Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User
出版日: | 発行: The Insight Partners | ページ情報: 英文 85 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.53円
北米の神経刺激装置：2030年市場予測-地域別分析-製品別、用途別、エンドユーザー別
出版日: 2024年04月05日
発行: The Insight Partners
ページ情報: 英文 85 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の神経刺激装置市場は、2022年に24億2,264万米ドルと評価され、2030年には50億80万米ドルに達すると予測され、2022～2030年のCAGRは9.5%と推定されます。

神経疾患の増加が北米神経刺激装置市場を活性化

高齢者人口は神経疾患にかかりやすいです。高齢者が罹患する一般的な神経疾患には、神経障害、パーキンソン病、アルツハイマー病、ジストニアなどがあります。米国国立衛生研究所（NIH）によると、世界人口の8.5％（すなわち約6億1,700万人）が65歳以上です。米国やカナダなどの国々では、高齢者人口の増加に伴う運動障害や精神疾患の有病率が高いです。パーキンソン財団によると、パーキンソン症状は平均年齢60歳でよくみられます。カナダ心理学会は、強迫性障害（OCD）はカナダの人口の約2％が罹患していると述べています。世界保健機関（WHO）は、てんかんは発作を引き起こす神経疾患で、世界中で5,000万人が罹患していると述べています。米国神経学会（American Academy of Neurology）によると、脳卒中は米国における死因の第3位で、アルツハイマー病がそれに続く第6位です。同じ供給源からの統計によると、約100万人のアメリカ人がパーキンソン病に罹患しており、毎年少なくとも6万人の新しい症例が報告されています。神経疾患の罹患率の増加は、うつ病や慢性疼痛などの生活習慣病と相まって、技術的に進歩した製品の採用を増加させています。WHOによると、神経疾患は世界の疾病負担の6.3％を占めています。また、同供給源によれば、神経疾患は世界中で主要な死因のひとつです。先進国では13.2％、中低所得国では16.8％の死亡原因となっています。高い死亡率と疾病負担は、長期的な解決策を統合する臨床的緊急性を必要とします。さらに、神経疾患の大きな負担に関する意識の高まりが、治療としての神経刺激装置の需要を高めています。したがって、神経疾患に罹患しやすい高齢者人口の増加、疾患の有病率の増加、神経疾患の多大な負担に関する意識の高まりが、神経刺激装置市場の成長を後押ししています。

北米の神経刺激装置市場概要

北米の神経刺激装置市場は、米国、カナダ、メキシコに区分されます。北米は、神経疾患の有病率の増加、研究開発への高い支出、米国食品医薬品局（FDA）による製品承認、技術の進歩により、世界の神経刺激装置市場で大きなシェアを占めると予想されます。神経疾患に罹患しやすい高齢者人口の増加は、予測期間中に同地域の市場成長に有利な機会を提供すると期待されています。さらに、脳疾患に対する懸念の高まりに対処するための政府からの支援の高まりが、この地域の市場成長を後押しすると期待されています。米国では、神経血管疾患の発生率が著しく上昇しており、国全体の主要な死因の一つとなっています。パーキンソン病（PD）などの神経疾患の罹患率の上昇、神経疾患に対する意識の高まり、経頭蓋刺激装置の開発への投資の増加は、米国における神経刺激装置市場全体を牽引する主要要因の一つです。脳深部刺激（DBS）装置は、パーキンソン病に伴う震えを効果的に制御することが確認されています。ドーパミンの数値低下やその他の遺伝的要因がパーキンソン病の主要原因となっています。

北米の神経刺激装置市場の収益と2030年までの予測（金額）

北米の神経刺激装置市場のセグメンテーション

北米の神経刺激装置市場は、製品、用途、エンドユーザー、国によって区分されます。

製品別では、北米の神経刺激装置市場は脊髄刺激装置、脳深部刺激装置、仙骨神経刺激装置、迷走神経刺激装置、その他に区分されます。脊髄刺激装置セグメントは2022年に最大の市場シェアを占めました。

用途別では、北米の神経刺激装置市場は疼痛管理、てんかん、尿失禁と便失禁、パーキンソン病、その他に分類されます。疼痛管理セグメントが2022年に最大の市場シェアを占めました。

エンドユーザー別では、北米の神経刺激装置市場は病院、専門クリニック、その他に区分されます。病院セグメントが2022年に最大の市場シェアを占めました。

国別では、北米の神経刺激装置市場は米国、カナダ、メキシコに区分されます。2022年の北米神経刺激装置市場シェアは米国が独占しました。

Medtronic Plc、Boston Scientific Corp、Abbott Laboratories、Nevro Corp、LivaNova Plc、Synapse Biomedical Inc、Nalu Medical Inc、ElectroCore Inc、MicroTransponder Inc、Mainstay Medicalは、北米神経刺激装置市場で事業を展開している大手企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブ概要

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米の神経刺激装置市場-主要産業力学

  • 市場促進要因
    • 神経疾患の有病率の増加
    • 脊髄損傷の症例の増加
  • 市場抑制要因
    • 専門家の不足
  • 市場機会
    • 神経刺激装置の進歩と承認の増加
  • 今後の動向
    • 非侵襲的治療に対する需要の高まり
  • 影響分析

第5章 神経刺激装置市場：北米市場分析

  • 北米の神経刺激装置市場売上実績、2022～2030年

第6章 北米の神経刺激装置市場：製品別収益と2030年までの予測

  • イントロダクション
  • 北米の神経刺激装置市場：2022年と2030年の製品別売上高シェア（%）
  • 脊髄刺激装置
  • 脳深部刺激装置
  • 仙骨神経刺激装置
  • 迷走神経刺激装置
  • その他

第7章 北米の神経刺激装置市場：用途別収益と2030年までの予測

  • イントロダクション
  • 北米の神経刺激装置市場：2022年と2030年の用途別売上高シェア（%）
  • 疼痛管理
  • てんかん
  • 尿失禁と便失禁
  • パーキンソン病
  • その他

第8章 北米の神経刺激装置市場：エンドユーザー別収益と2030年までの予測

  • イントロダクション
  • 北米の神経刺激装置市場：2022年と2030年のエンドユーザー別売上高シェア（%）
  • 病院
  • 専門クリニック
  • その他

第9章 北米の神経刺激装置市場：2030年までの収益と予測：国別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ

第10章 神経刺激装置市場-業界情勢

  • イントロダクション
  • 有機的展開
  • 無機的展開

第11章 企業プロファイル

  • Medtronic Plc
  • Boston Scientific Corp
  • Abbott Laboratories
  • Nevro Corp
  • LivaNova Plc
  • Synapse Biomedical Inc.
  • Nalu Medical, Inc
  • ElectroCore Inc
  • MicroTransponder Inc.
  • Mainstay Medical

第12章 付録

図表

List Of Tables

  • Table 1. Neurostimulation Devices Market Segmentation
  • Table 2. US Neurostimulation Devices Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. US Neurostimulation Devices Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US Neurostimulation Devices Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. Canada Neurostimulation Devices Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. Canada Neurostimulation Devices Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Canada Neurostimulation Devices Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Mexico Neurostimulation Devices Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Mexico Neurostimulation Devices Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Mexico Neurostimulation Devices Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Organic Developments Done by Companies
  • Table 12. Inorganic Developments Done by Companies
  • Table 13. Glossary of Terms, Neurostimulation Devices Market

List Of Figures

  • Figure 1. Neurostimulation Devices Market Segmentation, By Country
  • Figure 2. Neurostimulation Devices Market: Key Industry Dynamics
  • Figure 3. Neurostimulation Devices Market: Impact Analysis of Drivers and Restraints
  • Figure 4. North America Neurostimulation Devices Market Revenue (US$ Mn), 2020 - 2030
  • Figure 5. North America Neurostimulation Devices Market Revenue Share, by Product 2022 & 2030 (%)
  • Figure 6. Spinal Cord Stimulator: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Deep Brain Stimulator: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Sacral Nerve Stimulator: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Vagus Nerve Stimulator: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Others: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. North America Neurostimulation Devices Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 12. Pain Management: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Epilepsy: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Urinary and Fecal Incontinence: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Parkinson's Disease: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Others: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. North America Neurostimulation Devices Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 18. Hospitals & Clinics: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Specialty Clinics: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. North America: Neurostimulation Devices Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 22. North America: Neurostimulation Devices Market, by Country, 2022 & 2030 (%)
  • Figure 23. US: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Canada: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Mexico: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
目次
Product Code: BMIRE00030034

The North America neurostimulation devices market was valued at US$ 2,422.64 million in 2022 and is expected to reach US$ 5,000.80 million by 2030; it is estimated to register a CAGR of 9.5% from 2022 to 2030.

Increasing Prevalence of Neurological Disorders Fuels North America Neurostimulation Devices Market

Geriatric population is susceptible to neurological diseases. Common neurological disorders affecting older people are neuropathy, Parkinson's disease, Alzheimer's disease, dystonia, and others. As per the National Institutes of Health (NIH), 8.5% of the world's population (i.e., around 617 million people) is aged 65 years and above. Countries such as the US and Canada have high prevalence rates of movement disorders and psychiatric disorders associated with growing geriatric populations. According to the Parkinson's Foundation, Parkinson's symptoms are common at an average age of 60. The Canadian Psychological Association states that obsessive-compulsive disorder (OCD) affects about 2% of the population in Canada. The World Health Organization (WHO) states that epilepsy is a seizure-causing neurological disorder that affects 50 million people worldwide. As per the American Academy of Neurology, stroke is the third leading cause of death in the US, followed by Alzheimer's as the sixth leading cause of death. Statistics from the same source show that nearly one million Americans are affected by Parkinson's, and at least 60,000 new cases are reported annually. The growing incidence of neurological diseases coupled with lifestyle-related disorders such as depression and chronic pain leads to the increasing adoption of technologically advanced products. According to the WHO, nervous disorders contribute to 6.3% of the global disease burden. Also, according to the same source, the disorders are one of the leading causes of deaths across the world. They cause 13.2% of deaths in developed countries and 16.8% in low- and middle-income countries. High mortality and disease burden necessitate the clinical urgency for integrating long-term solutions. Furthermore, growing awareness regarding the tremendous burden of neurological disorders has increased the demand for neurostimulators as a therapy. Therefore, the growing geriatric population prone to neurological diseases, increasing prevalence of the diseases, and rising awareness regarding the tremendous burden of neurological disorders drive the neurostimulation devices market growth.

North America Neurostimulation Devices Market Overview

The North America neurostimulation devices market is segmented into the US, Canada, and Mexico. North America is expected to hold a significant share of the global neurostimulation devices market owing to the growing prevalence of neurological diseases, high spending on research and development, product approvals by the US Food and Drug Administration (FDA), and technological advances. The rising geriatric population prone to neurological diseases is expected to offer lucrative opportunities for market growth in the region during the forecast period. Further, the growing support from the government to address the rising concerns about brain diseases is expected to boost market growth in the region. In the US, the incidence of neurovascular diseases is rising significantly, and it is among the leading causes of death across the country. Rising incidence of neurological diseases such as Parkinson's disease (PD), increasing awareness about neurological disorders, and growing investments in developing transcranial stimulators are among the main factors driving the overall neurostimulation devices market in the US. Deep brain stimulation (DBS) devices have been observed to control the tremors associated with Parkinson's disease effectively. Low dopamine readings and other genetic factors are among the main causes of Parkinson's disease.

North America Neurostimulation Devices Market Revenue and Forecast to 2030 (US$ Million)

North America Neurostimulation Devices Market Segmentation

The North America neurostimulation devices market is segmented based on product, application, end user, and country.

Based on product, the North America neurostimulation devices market is segmented into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and others. The spinal cord stimulator segment held the largest market share in 2022.

In terms of application, the North America neurostimulation devices market is categorized into pain management, epilepsy, urinary and fecal incontinence, Parkinson's disease, and others. The pain management segment held the largest market share in 2022.

By end user, the North America neurostimulation devices market is segmented into hospitals, specialty clinics, and others. The hospitals segment held the largest market share in 2022.

Based on country, the North America neurostimulation devices market is segmented into the US, Canada, and Mexico. The US dominated the North America neurostimulation devices market share in 2022.

Medtronic Plc, Boston Scientific Corp, Abbott Laboratories, Nevro Corp, LivaNova Plc, Synapse Biomedical Inc, Nalu Medical Inc, ElectroCore Inc, MicroTransponder Inc, and Mainstay Medical are some of the leading companies operating in the North America neurostimulation devices market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Neurostimulation Devices Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Neurological Disorders
    • 4.1.2 Rising Cases of Spinal Cord Injury
  • 4.2 Market Restraints
    • 4.2.1 Lack of Expert Professionals
  • 4.3 Market Opportunities
    • 4.3.1 Growing Advances and Approvals for Neurostimulation Devices
  • 4.4 Future Trends
    • 4.4.1 Rising Demand for Noninvasive Treatment
  • 4.5 Impact Analysis

5. Neurostimulation Devices Market - North America Market Analysis

  • 5.1 North America Neurostimulation Devices Market Revenue (US$ Mn), 2022 - 2030

6. North America Neurostimulation Devices Market - Revenue and Forecast to 2030 - by Product

  • 6.1 Overview
  • 6.2 North America Neurostimulation Devices Market Revenue Share, by Product 2022 & 2030 (%)
  • 6.3 Spinal Cord Stimulator
    • 6.3.1 Overview
    • 6.3.2 Spinal Cord Stimulator: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Deep Brain Stimulator
    • 6.4.1 Overview
    • 6.4.2 Deep Brain Stimulator: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Sacral Nerve Stimulator
    • 6.5.1 Overview
    • 6.5.2 Sacral Nerve Stimulator: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Vagus Nerve Stimulator
    • 6.6.1 Overview
    • 6.6.2 Vagus Nerve Stimulator: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.7 Others
    • 6.7.1 Overview
    • 6.7.2 Others: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Neurostimulation Devices Market - Revenue and Forecast to 2030 - by Application

  • 7.1 Overview
  • 7.2 North America Neurostimulation Devices Market Revenue Share, by Application 2022 & 2030 (%)
  • 7.3 Pain Management
    • 7.3.1 Overview
    • 7.3.2 Pain Management: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Epilepsy: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Urinary and Fecal Incontinence
    • 7.5.1 Overview
    • 7.5.2 Urinary and Fecal Incontinence: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Parkinson's Disease
    • 7.6.1 Overview
    • 7.6.2 Parkinson's Disease: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Neurostimulation Devices Market - Revenue and Forecast to 2030 - by End User

  • 8.1 Overview
  • 8.2 North America Neurostimulation Devices Market Revenue Share, by End User 2022 & 2030 (%)
  • 8.3 Hospitals
    • 8.3.1 Overview
    • 8.3.2 Hospitals: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Specialty Clinics
    • 8.4.1 Overview
    • 8.4.2 Specialty Clinics: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Neurostimulation Devices Market - Revenue and Forecast to 2030 - Country Analysis

  • 9.1 North America: Neurostimulation Devices Market
    • 9.1.1 Overview
    • 9.1.2 North America: Neurostimulation Devices Market, by Country, 2022 & 2030 (%)
      • 9.1.2.1 US: Neurostimulation Devices Market - Revenue and Forecast to 2030 (USD Million)
      • 9.1.2.2 US: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.2.2.1 US: Neurostimulation Devices Market, by Product, 2020-2030 (US$ Million)
        • 9.1.2.2.2 US: Neurostimulation Devices Market, by Application, 2020-2030 (US$ Million)
        • 9.1.2.2.3 US: Neurostimulation Devices Market, by End User, 2020-2030 (US$ Million)
      • 9.1.2.3 Canada: Neurostimulation Devices Market - Revenue and Forecast to 2030 (USD Million)
      • 9.1.2.4 Canada: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.2.4.1 Canada: Neurostimulation Devices Market, by Product, 2020-2030 (US$ Million)
        • 9.1.2.4.2 Canada: Neurostimulation Devices Market, by Application, 2020-2030 (US$ Million)
        • 9.1.2.4.3 Canada: Neurostimulation Devices Market, by End User, 2020-2030 (US$ Million)
      • 9.1.2.5 Mexico: Neurostimulation Devices Market - Revenue and Forecast to 2030 (USD Million)
      • 9.1.2.6 Mexico: Neurostimulation Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.2.6.1 Mexico: Neurostimulation Devices Market, by Product, 2020-2030 (US$ Million)
        • 9.1.2.6.2 Mexico: Neurostimulation Devices Market, by Application, 2020-2030 (US$ Million)
        • 9.1.2.6.3 Mexico: Neurostimulation Devices Market, by End User, 2020-2030 (US$ Million)

10. Neurostimulation Devices Market-Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Developments
    • 10.2.1 Overview
  • 10.3 Inorganic Developments
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Medtronic Plc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Boston Scientific Corp
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Abbott Laboratories
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Nevro Corp
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 LivaNova Plc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Synapse Biomedical Inc.
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Nalu Medical, Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 ElectroCore Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 MicroTransponder Inc.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 Mainstay Medical
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms